Synthesis of Chromone, Quinolone, and Benzoxazinone Sulfonamide Nucleosides as Conformationally Constrained Inhibitors of Adenylating Enzymes Required for Siderophore Biosynthesis
作者:Curtis A. Engelhart、Courtney C. Aldrich
DOI:10.1021/jo400976f
日期:2013.8.2
catalyzes the first committed step of mycobactin biosynthesis in Mycobacterium tuberculosis (Mtb) and is responsible for the incorporation of salicylic acid into the mycobactin siderophores. 5′-O-[N-(Salicyl)sulfamoyl]adenosine (Sal-AMS) is an extremely potent nucleoside inhibitor of MbtA that possesses excellent activity against whole-cell Mtb but suffers from poor bioavailability. In an effort to improve
MbtA 催化结核分枝杆菌( Mtb )中分枝杆菌素生物合成的第一个关键步骤,并负责将水杨酸掺入分枝杆菌素铁载体中。5'- O -[ N -(Salicyl)sulfamoyl]adenosine (Sal-AMS) 是一种极其有效的 MbtA 核苷抑制剂,对全细胞Mtb具有出色的活性但生物利用度差。为了提高生物利用度,我们设计了四种构象受限的 Sal-AMS 类似物,它们在计算和结构研究的基础上去除了两个可旋转键和电离氨基磺酸酯基团。在此,我们描述了 Sal-AMS 的色酮-、喹诺酮-和苯并恶嗪酮-3-磺酰胺衍生物的合成、生化和微生物学评价。我们开发了新的化学方法来从常见的 β-酮磺酰胺中间体组装这三个杂环。色酮-和喹诺酮-3-磺酰胺中间体的合成特征是使用二甲基甲酰胺二甲基乙缩醛对β-酮磺酰胺进行甲酰化,以提供烯胺酮,该烯胺酮可以通过加成消除反应与苯酚发生分子内反应或与伯胺发生分子间反应。苯并嗪酮-3-磺酰胺是通过
Novel phenyl-substituted sulfonamides
申请人:E.I. DU PONT DE NEMOURS AND COMPANY
公开号:EP0107979A1
公开(公告)日:1984-05-09
Sulfonamide derivatives of the formula
wherein J is phenyl fused to a specified carbocyclic or heterocyclic ring, said phenyl and said ring both being optionally substituted;
R is H or CH3;
W is 0 or S;
A is substituted monocylic or bicyclic heterocyclic group;
and their agriculturally suitable salts, exhibit herbicidal and plant growth regulant activities. They may be formulated for agricultural use in conventional manner.
The novel compounds may be made in various ways. e.g. by reacting a novel sulfonylisocyanate or sulfonylisothiocyanate of formula JSO2NCW with an appropriate heterocyclic amine of formula RHNA.
式中的磺酰胺衍生物
其中 J 是与特定碳环或杂环融合的苯基,所述苯基和所述环均被任选取代;
R 是 H 或 CH3
W 是 0 或 S;
A 是被取代的单环或双环杂环基团;
及其农用盐类具有除草和植物生长调节活性。它们可按常规方法配制成农用制剂。
这些新型化合物可以通过多种方法制得,例如,将式 JSO2NCW 的新型磺酰基异氰酸酯或磺酰基异硫氰酸酯与适当的式 RHNA 的杂环胺反应。
Loewe Werner, Matzanke Norbert, Ruetjes Thomas, Arch. Pharm, 327 (1994) N 12, S 819-823